See the DrugPatentWatch profile for klonopin

Based on the information provided, there is not enough data to determine the exact market share that Bindo Pharma controls of the 1mg Klonopin (clonazepam) market. However, it is possible to gather some insights from DrugPatentWatch.com [1] regarding the patents and market exclusivity of Klonopin.

Klonopin, a medication used to treat seizure disorders, panic disorder, and anxiety, has patent protection in various countries. The active ingredient, clonazepam, is a benzodiazepine derivative that was first patented in 1964 [1]. In the United States, the original patent for clonazepam expired in 1991, but Roche (the innovator company) maintained market exclusivity through 2003 due to pediatric exclusivity and orphan drug exclusivity [1].

Bindo Pharma, an India-based pharmaceutical company, may have a presence in the clonazepam market, but the specific market share is not publicly available or mentioned in the provided source. Bindo Pharma's portfolio includes various pharmaceutical products, including generic drugs [2]. However, without additional information, it is not possible to accurately answer the question.

In summary, while Bindo Pharma may have a presence in the clonazepam market, the exact market share is not publicly available or mentioned in the provided source. For a more accurate answer, additional information regarding Bindo Pharma's sales, revenue, and market share specific to clonazepam would be required.

Sources:

1. DrugPatentWatch.com. (n.d.). Clonazepam (marketed as Klonopin) - DrugPatentWatch. Retrieved from https://www.drugpatentwatch.com/drugs/clonazepam
2. Bindo Pharma. (n.d.). About Us. Retrieved from https://bindopharma.com/about-us/